CRISPR Therapeutics AG (CRSP)
NASDAQ: CRSP
· Real-Time Price · USD
59.72
0.90 (1.53%)
At close: Aug 15, 2025, 3:59 PM
59.96
0.40%
After-hours: Aug 15, 2025, 07:57 PM EDT
CRISPR Therapeutics Income Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Revenue | 37.36M | 36.98M | 36.62M | 201.62M | 201.02M | 270.5M | 370M | 170.01M | 170.1M | 100.26M | 436K | 12.78M | 13.01M | 913.06M | 913.08M | 900.93M | 900.75M | 588K |
Cost of Revenue | 164.91M | 125.64M | 119.93M | 139.93M | 152.2M | 139.86M | 130.25M | 117.07M | 132.51M | 121.8M | 110.25M | 238.35M | 221.95M | 214.97M | 204.27M | 151.72M | 200.26M | 232.7M |
Gross Profit | -127.56M | -88.65M | -83.31M | 61.7M | 48.82M | 130.65M | 239.75M | 52.93M | 37.59M | -21.54M | -109.81M | -225.57M | -208.94M | 698.08M | 708.81M | 749.21M | 700.48M | -232.11M |
Operating Income | -552.47M | -474.4M | -466.56M | -332.39M | -354.68M | -298.64M | -222.54M | -423.66M | -473.64M | -561.68M | -673.16M | -687.32M | -633.78M | 312.1M | 373.53M | 411.46M | 447.92M | -395.39M |
Interest Income | n/a | n/a | n/a | n/a | 20.67M | 39.08M | 39.08M | 39.08M | 18.41M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Pretax Income | -463.82M | -381.69M | -362.67M | -236.47M | -263.15M | -214.84M | -150.72M | -360.35M | -423.74M | -526.64M | -650.5M | -673.95M | -626.57M | 316.51M | 379.53M | 415.85M | 451.36M | -391.29M |
Net Income | -467.8M | -385.66M | -366.25M | -239.59M | -265.8M | -217.14M | -153.61M | -353.53M | -415.93M | -524.02M | -650.17M | -680.85M | -633.45M | 311.61M | 377.66M | 411.87M | 446.58M | -392.3M |
Selling & General & Admin | 73.75M | 74.32M | 72.98M | 71.33M | 72.2M | 71.75M | 76.16M | 80.85M | 89.56M | 96.8M | 102.46M | 105.42M | 102.77M | 106.31M | 102.8M | 104.44M | 101.63M | 93.17M |
Research & Development | 301.85M | 307.28M | 306.13M | 323.96M | 332.5M | 358.74M | 387.33M | 395.74M | 421.67M | 443.33M | 461.64M | 492.56M | 481.26M | 466.31M | 438.63M | 386.53M | 352.21M | 303.32M |
Other Expenses | 45.15M | n/a | n/a | 20M | 20M | 20M | 20M | n/a | n/a | n/a | -762K | 1.44M | 2.54M | 3.29M | 6M | 4.38M | 3.44M | 4.1M |
Operating Expenses | 424.91M | 385.75M | 383.26M | 394.09M | 403.5M | 429.29M | 462.29M | 476.6M | 511.23M | 540.14M | 563.35M | 596.67M | 582.22M | 570.31M | 539.55M | 489.46M | 452.83M | 395.98M |
Interest Expense | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 589.83M | 511.39M | 503.19M | 534.02M | 555.7M | 569.14M | 592.54M | 593.67M | 643.74M | 661.93M | 673.6M | 700.1M | 646.79M | 600.96M | 539.55M | 489.46M | 452.83M | 395.98M |
Income Tax Expense | 1.39M | 3.97M | 3.59M | 3.12M | 1.83M | 1.47M | 2.06M | -7.64M | -7.81M | -2.61M | -325K | 6.9M | 6.88M | 4.9M | 1.87M | 3.98M | 4.77M | 1.01M |
Shares Outstanding (Basic) | 87.07M | 85.94M | 85.46M | 85.23M | 84.92M | 81.79M | 79.69M | 79.41M | 79.09M | 78.68M | 78.34M | 77.92M | 77.43M | 77.1M | 76.65M | 76.14M | 75.83M | 74.94M |
Shares Outstanding (Diluted) | 87.07M | 85.94M | 85.46M | 85.23M | 84.92M | 81.79M | 81.32M | 79.41M | 79.09M | 78.68M | 78.34M | 78.02M | 77.51M | 77.1M | 76.65M | 76.29M | 80.45M | 75.01M |
EPS (Basic) | -5.43 | -4.52 | -4.37 | -2.81 | -3.21 | -2.7 | -1.94 | -4.47 | -5.3 | -6.72 | -8.37 | -8.8 | -8.23 | 4.18 | 4.99 | 5.30 | 5.65 | -5.66 |
EPS (Diluted) | -5.43 | -4.52 | -4.37 | -2.83 | -3.23 | -2.72 | -1.96 | -4.47 | -5.3 | -6.72 | -8.37 | -8.8 | -8.23 | 3.61 | 4.42 | 4.73 | 5.08 | -5.66 |
EBITDA | -538.15M | -455.24M | -447.31M | -313.08M | -335.17M | -279.02M | -202.7M | -402.88M | -452.76M | -538.49M | -648.99M | -662.73M | -608.89M | 333.38M | 391.48M | 425.72M | 459.18M | -385.58M |
EBIT | -295.16M | -446.42M | -438.59M | -312.4M | -334.68M | -278.64M | -202.54M | -423.66M | -473.64M | -561.68M | -673.16M | -687.32M | -633.78M | 312.85M | 374.28M | 412.21M | 448.67M | -395.39M |
Depreciation & Amortization | 14.38M | 19.22M | 19.32M | 19.38M | 19.5M | 19.62M | 19.84M | 20.78M | 20.88M | 23.18M | 24.17M | 24.59M | 24.89M | 21.28M | 17.95M | 14.26M | 11.27M | 9.81M |